Overview

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Pregabalin
Tolterodine Tartrate